Literature DB >> 12869036

IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

C Schwarze1, B Terjung, P Lilienweiss, U Beuers, V Herzog, T Sauerbruch, U Spengler.   

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) of IgG class have been described at high prevalence in autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). Data on IgA class ANCA in these diseases are limited. The aim of this study was to determine the prevalence and fluorescence patterns of IgA class ANCA in AIH and PSC and to examine a relationship between the presence of IgA ANCA and clinical characteristics in these patients. Sera from 35 patients with PSC (21 with concomitant inflammatory bowel disease), 40 patients with AIH and 10 healthy controls were studied. ANCA were detected on ethanol-fixed neutrophils using an indirect immunofluorescence technique. ANCA of the IgA class were found in 20% of sera from patients with PSC and in 50% of AIH sera. The majority of AIH patients with IgA class ANCA showed a 'classical' perinuclear staining pattern, whereas the 'classical' and 'atypical' perinuclear fluorescence patterns were distributed equally in PSC. In sera containing IgG and IgA class ANCA simultaneously, IgG class ANCA showed an 'atypical' pANCA fluorescence pattern whereas IgA class ANCA produced a 'classical' perinuclear staining. The presence of IgA class ANCA was not associated with disease-specific clinical characteristics. IgA class ANCA are more frequently detected in sera of patients with AIH than PSC. The diversity of fluorescence patterns points to different target antigens of IgA class ANCA with distinct subcellular localizations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869036      PMCID: PMC1808764          DOI: 10.1046/j.1365-2249.2003.02195.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Factors related to the presence of IgA class antineutrophil cytoplasmic antibodies in ulcerative colitis.

Authors:  M Esteve; J Mallolas; J Klaassen; A Abad-Lacruz; F Gonzàlez-Huix; E Cabré; F Fernández-Bañares; M Menacho; E Condom; J Martí-Ragué; M A Gassull
Journal:  Am J Gastroenterol       Date:  1998-04       Impact factor: 10.864

2.  Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins.

Authors:  B Terjung; V Herzog; H J Worman; I Gestmann; C Bauer; T Sauerbruch; U Spengler
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

3.  Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD).

Authors:  C Roozendaal; M H Zhao; G Horst; C M Lockwood; J H Kleibeuker; P C Limburg; G F Nelis; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

4.  Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass.

Authors:  D Bansi; R Chapman; K Fleming
Journal:  J Hepatol       Date:  1996-05       Impact factor: 25.083

5.  Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1.

Authors:  T Orth; G Gerken; R Kellner; K H Meyer zum Büschenfelde; W J Mayet
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

6.  Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease with special attention for IgA-class antibodies.

Authors:  P Gigase; L S De Clerck; K A Van Cotthem; C H Bridts; W J Stevens; M Van Outryve; P A Pelckmans
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

Review 7.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

Authors:  J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik
Journal:  Am J Clin Pathol       Date:  1999-04       Impact factor: 2.493

8.  Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.

Authors:  R S Walmsley; M H Zhao; M I Hamilton; A Brownlee; P Chapman; R E Pounder; A J Wakefield; C M Lockwood
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

9.  Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features.

Authors:  C Roozendaal; A W Van Milligen de Wit; E B Haagsma; G Horst; C Schwarze; H H Peter; J H Kleibeuker; J W Tervaert; P C Limburg; C G Kallenberg
Journal:  Am J Med       Date:  1998-11       Impact factor: 4.965

10.  Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis.

Authors:  T Orth; R Kellner; O Diekmann; J Faust; K H Meyer zum Büschenfelde; W J Mayet
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

View more
  10 in total

Review 1.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 2.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

3.  IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Authors:  Esha Oommen; Amber Hummel; Lisa Allmannsberger; David Cuthbertson; Simon Carette; Christian Pagnoux; Gary S Hoffman; Dieter E Jenne; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry Moreland; Philip Seo; Antoine Sreih; Steven R Ytterberg; Peter A Merkel; Ulrich Specks; Paul A Monach
Journal:  Clin Exp Rheumatol       Date:  2017-03-01       Impact factor: 4.473

Review 4.  Serological biomarkers for management of primary sclerosing cholangitis.

Authors:  David Tornai; Peter Laszlo Ven; Peter Laszlo Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2022-06-07       Impact factor: 5.374

Review 5.  Pathogenesis of primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Emina Halilbasic; Peter Fickert; Michael Trauner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-12       Impact factor: 3.043

Review 6.  Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.

Authors:  Takashi Himoto; Mikio Nishioka
Journal:  Auto Immun Highlights       Date:  2013-02-22

Review 7.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

8.  Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project.

Authors:  Anna Svärd; Alf Kastbom; Asa Reckner-Olsson; Thomas Skogh
Journal:  Arthritis Res Ther       Date:  2008-07-04       Impact factor: 5.156

Review 9.  Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.

Authors:  Albert J Czaja
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

10.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.